AnteoTech’s COVID-19 antigen and Flu A&B test distinguishes SARS-Cov-2, flu in under 15 minutes

AnteoTech’s COVID-19 antigen and Flu A&B test distinguishes SARS-Cov-2, flu in under 15 minutes


  • Post By : Kumar Jeetendra

  • Source: AnteoTech Ltd.

  • Date: 23 Aug,2020

AnteoTech Ltd has developed proof-of-concept COVID-19 antigen and Flu A&B point-of-care lateral flow tests which could detect the existence of SARS-Cov-2 and influenza in under 15 minutes. The tests utilize AnteoTech’s patented AnteoBind™ activated europium technologies and provide considerably higher sensitivity than that provided by currently available COVID-19 tests. AnteoTech intends for the tests to be combined into one multiplex test platform and be available in no more than 6–9 months subsequent clinical trials and regulatory approvals. Once installed, the portable test can significantly reduce COVID-19 spread by enabling detection and quarantine of infected people before symptoms develop. AnteoTech is a Brisbane-based company which specializes in Implementing next-generation surface direction technologies to address challenges in a range of markets, such as point-of-care diagnostics.

The development of this new platform marks a critical step in our collective journey to halt the spread of COVID-19. By leveraging many years of expert insight in the form of our AnteoBind europium nanoparticle technology and applying it to this unique challenge, we’re enabling detection of the lower viral particle levels seen in earlier stages of COVID-19 infection — levels which aren’t detectable with current gold-based diagnostics. As a result, we’re opening the possibility for better clinical decision-making and earlier direction of patients into quarantine to curtail disease spread.”-Derek Thomson, CEO of AnteoTech

Together with COVID-19 causing extreme economic and societal devastation worldwide, authorities and health providers continue to seek effective strategies to mitigate its spread. Mobilization of rapid and accurate testing is a crucial part of a comprehensive disease containment plan, allowing for swift identification of active instances and, consequently, early quarantine. However, investigation of conventional swab tests now requires expensive equipment, highly trained staff and must typically be done in massive hospitals or pathology labs. Further, testing in this manner might take several hours to generate results, undermining prompt clinical responses.

To conquer, AnteoTech’s new stage will take advantage of a patented AnteoBind assay surface that, with the usage of a mobile Axxin lateral flow reader, allows for quick, reproducible, and high-sensitivity outcomes without the need for highly trained employees and complex testing infrastructure.

Having successfully developed the proof-of-concept assays, we’re in a position to confidently proceed with the next steps to bring the platform to market. We’re now eagerly exploring opportunities for collaboration with device manufacturers to enable expedited production and commercialization of what looks to be an unmatched contribution to the COVID-19 point-of-care diagnostics space.”-Derek Thomson

AnteoTech’s COVID-19 development program has been initiated in late March 2020 and is backed by over 10 decades of rich experience in the creation of cutting edge bioconjugation and coating solutions. Over the coming weeks, the COVID-19 antigen double testing stage will enter another phase of development to optimize function, further enhance the lower limitation of viral particle detection and run clinical studies for targeted populations and configurations. AnteoTech is currently preparing for outsourced scaled production to make sure it could meet growing market need.

Along with the COVID-19 multiplex assay, a comprehensive body of work and testing was undertaken at AnteoTech’s Brisbane labs to develop several other fast tests, such as a stage for the early detection of sepsis.


About Author